This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Genprex’s 8K filing here.
About Genprex
Genprex, Inc, a clinical-stage gene therapy company, focuses on developing gene-based therapies for patients with cancer and diabetes in the United States. The company's lead product candidate is REQORSA (GPX-001), which is in preclinical trials to treat non-small cell lung cancer and small cell lung cancer; and GPX-002, which is in preclinical trials to treat type 1 and type 2 diabetes.
Featured Stories
- Five stocks we like better than Genprex
- 3 REITs to Buy and Hold for the Long Term
- Semtech Stock Climbs as AI Boom Drives Turnaround Success
- What is a support level?
- 3 Companies Leading the Way With Aggressive Stock Buybacks
- How Investors Can Identify and Successfully Trade Gap-Down Stocks
- Is It Time to Buy Nuclear Energy Stocks After the Latest Dip?
